The rate of breast cancer deaths in the U.S. has dramatically declined since 1950. As of 2023, the death rate from breast cancer was **** per 100,000 population. However, cancer is a serious public health issue in the United States and is the second leading cause of death among women. Breast cancer incidence Breast cancer symptoms include lumps or thickening of the breast tissue and may include changes to the skin. Breast cancer is driven by many factors, but age is a known risk factor. Among all age groups, the highest number of invasive breast cancer cases were among those aged 60 to 69. The incidence rate of new breast cancer cases is higher in some ethnicities than others. White, non-Hispanic women have the highest incidence rate of breast cancer, followed by non-Hispanic Black women. Breast cancer treatment Breast cancer treatments usually involve several methods, including surgery, chemotherapy and biological therapy. Types of cancer diagnosed at earlier stages often require fewer treatments. A majority of early stage breast cancer cases in the U.S. receive breast conserving surgery and radiation therapy.

This statistic shows the number of breast cancer deaths in the United States from 1999 to 2021, by gender. The highest number of breast cancer deaths in the given period was 42,465, reported in 2018. The lowest number was reported in 2008, with 40,589 deaths.

Breast cancer is the most common cancer among women, causing considerable burden and mortality. Demographic and lifestyle transitions in low and low-middle income countries have given rise to its increased incidence. The successful management of cancer relies on evidence-based policies taking into account national epidemiologic settings. We aimed to report the national and subnational trends of breast cancer incidence, mortality, years of life lost (YLL) and mortality to incidence ratio (MIR) since 1990. As part of the National and Subnational Burden of Diseases project, we estimated incidence, mortality and YLL of breast cancer by sex, age, province, and year using a two-stage spatio-temporal model, based on the primary dataset of national cancer and death registry. MIR was calculated as a quality of care indicator. Age-period-cohort analysis was used to distinguish the effects of these three collinear factors. A significant threefold increase in age-specific incidence at national and subnational levels along with a twofold extension of provincial disparity was observed. Although mortality has slightly decreased since 2000, a positive mortality annual percent change was detected in patients aged 25–34 years, leading to raised YLLs. A significant declining pattern of MIR and lower provincial MIR disparity was observed. We observed a secular increase of breast cancer incidence. Further evaluation of risk factors and developing national screening policies is recommended. A descending pattern of mortality, YLL and MIR at national and subnational levels reflects improved quality of care, even though mortality among younger age groups should be specifically addressed.

ObjectiveTo estimate the risk of death from lung cancer in patients treated for breast cancer (BC) in relation to the general population.MethodsBC data, covering 2000 to 2015, were extracted from the Surveillance, Epidemiology and End Results-18 (SEER-18) cancer registry database. A comparison of lung cancer attributed mortality between BC patients and the general population was performed using standardized mortality ratios (SMRs) and SMRs conditional on survival length (cSMRs). Prognostic factors of lung cancer mortality were identified using flexible parametric modelling. Our model adjusts the effect of downstream (histopathological BC tumor grade and hormone receptor status) and upstream (age at diagnosis, ethnicity, and marital status) factors.ResultsThe median follow-up was 6.4 years (interquartile range, 3.0–10.3 years). BC cases who received only radiotherapy (cSMR = 0.93; 95%CI: 0.77–1.13), only chemotherapy (cSMR = 0.91; 0.62–1.33), and radio-and chemotherapy (cSMR = 1.04; 0.77–1.39) had no evidence of increased lung cancer mortality relative to the general population. The adjusted model identified that lung cancer mortality was higher for women who were older at diagnosis compared to those

In 2019, Ghana registered over ***** total deaths due to breast cancer, increasing from the previous year. The number of breast cancer deaths peaked in 2019 as it kept an upward trend since 2000. That year, the number of breast cancer deaths reached *****.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

S1 File. Community SES information. S1 Fig. Scatterplot of the relationship between community land price (A), neighborhood income (B), education level (C), and employment rate (D), with stomach cancer morbidity and mortality for men and women in Kanagawa, Japan, 2000–2015. Each plot shows data per year and community. 1$ = 133 Japanese Yen, the rate on March 20, 2023. S2 Fig. Scatterplot of the relationship between community land price (A), neighborhood income (B), education level (C), and employment rate (D), with colorectal cancer morbidity and mortality for men and women in Kanagawa, Japan, 2000–2015. Each plot shows data per year and community. 1$ = 133 Japanese Yen, the rate on March 20, 2023. S3 Fig. Scatterplot of the relationship between community land price (A), neighborhood income (B), education level (C), and employment rate (D), with liver cancer morbidity and mortality for men and women in Kanagawa, Japan, 2000–2015. Each plot shows data per year and community. 1$ = 133 Japanese Yen, the rate on March 20, 2023. S4 Fig. Scatterplot of the relationship between community land price (A), neighborhood income (B), education level (C), and employment rate (D), with breast cancer morbidity and mortality for women in Kanagawa, Japan, 2000–2015. Each plot shows data per year and community. 1$ = 133 Japanese Yen, the rate on March 20, 2023. S1 Table. Correlation coefficients of the aging rate, screening rate, and community SES indicators in Kanagawa, Japan, 2000–2015. S2 Table. VIF of the Poisson regression using community SES indicator, aging rate, and year as explanatory variables. S3 Table. VIF of the Poisson regression using community SES indicator, aging rate, year, and municipality code as explanatory variables. S4 Table. Multilevel analysis by the year for cancer morbidity in Kanagawa, Japan, 2000–2015. S5 Table. Multilevel analysis by the year for cancer mortality in Kanagawa, Japan, 2000–2015. S6 Table. Multilevel analysis by the municipality code for cancer morbidity in Kanagawa, Japan, 2000–2015. S7 Table. Multilevel analysis by the municipality code for cancer mortality in Kanagawa, Japan, 2000–2015. S8 Table. Correlation coefficients of community SES indicators by year in Kanagawa, Japan, 2000–2015. S9 Table. Average and SD of land price, neighborhood income, education level, employment rate, morbidity, and mortality for each cancer type in urban, town, and rural areas in Kanagawa, Japan, 2000–2015. S10 Table. Linear regression with SES quartiles, year, and aging rate as explanatory variables and cancer incidence or mortality as response variables. S11 Table. Number of deaths for each type of cancer registered in the vital statistics in Kanagawa, Japan, 2000–2015. S12 Table. Regression coefficients of community SES indicators by Poisson regression using community SES indicator and year as explanatory variables and age-adjusted mortality as the response variable in Kanagawa, Japan, 2000–2015. (ZIP)

Basic Metadata

*Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.

**Blank Cells: Rates not calculated for fewer than 5 events. Rates not calculated in cases where zip code is unknown.

***API: Asian/Pacific Islander. ***AIAN: American Indian/Alaska Native.

Prepared by: County of San Diego, Health & Human Services Agency, Public Health Services, Community Health Statistics Unit, 2019.

Code Source: ICD-9CM - AHRQ HCUP CCS v2015. ICD-10CM - AHRQ HCUP CCS v2018. ICD-10 Mortality - California Department of Public Health, Group Cause of Death Codes 2013; NHCS ICD-10 2e-v1 2017.

Data Guide, Dictionary, and Codebook: https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/CHS/Community%20Profiles/Public%20Health%20Services%20Codebook_Data%20Guide_Metadata_10.2.19.xlsx

Standardised mortality ratios for deaths from all causes and from eight causes in Glasgow from 2000 to 2012 . The Glasgow ratios are a percentage of the numbers dead in Glasgow from that cause that would be expected for Glasgow City if it had the same age/sex-specific death rates as Scotland as a whole. The eight causes are: all cancers; Stomach Cancer; Large Intestine cancer; Trachea, Bronchus, Lung cancer; Female breast cancer; Ischaemic Heart Disease; CerebroVascular and Pneumonia. They were calculated using the 'rebased' mid-year population estimates for 2002 to 2011- see Births and Deaths Rates: breaks in series circa 2011 Data extracted 2014-04-09 from the General Register Office for Scotland Licence: None

For each region, attained-age- and birth-cohort-specific annual changes in the incidence of stage 2–4 breast cancer in the 8-year period 2000–2007.

In 2022, 175 females per 100,000 population were registered in England as newly diagnosed with breast cancer. This was an overall increase in comparison to the last few years' rate of registration. This statistic shows the rate of newly diagnosed female cases of breast cancer per 100,000 population in England from 1995 to 2022.

BackgroundPatients who received private health care appear to have better survival from breast cancer compared to those who received public care. This study investigated if this applied to New Zealand women and identified factors that could explain such disparities.MethodsThis study involved all women who were diagnosed with primary breast cancer in two health regions in New Zealand, covering about 40% of the national population, between June 2000 and May 2013. Patients who received public care for primary treatment, mostly surgical treatment, were compared with those who received private care in terms of demographics, mode of presentation, disease factors, comorbidity index and treatment factors. Cox regression modelling was performed with stepwise adjustments, and hazards of breast cancer specific mortality associated with the type of health care received was assessed.ResultsOf the 14,468 patients, 8,916 (61.6%) received public care. Compared to patients treated in private care facilities, they were older, more likely to be Māori, Pacifika or Asian and to reside in deprived neighbourhoods and rural areas, and less likely to be diagnosed with early staged cancer and to receive timely cancer treatments. They had a higher risk of mortality from breast cancer (hazard ratio: 1.95; 95% CI: 1.75, 2.17), of which 80% (95% CI: 63%, 100%) was explained by baseline differences, particularly related to ethnicity, stage at diagnosis and type of loco-regional therapy. After controlling for these demographic, disease and treatment factors, the risk of mortality was still 14% higher in the public sector patients.ConclusionsEthnicity, stage at diagnosis and type of loco-regional therapy were the three key contributors to survival disparities between patients treated in public and private health care facilities in New Zealand. The findings underscore the need for more efforts to improve the quality, timeliness and equitability of public cancer care services.

BackgroundMetastatic breast cancer (MBC) remains a devastating and incurable disease. Over the past decade, the implementation of clinical trials both with and without molecular targeted therapeutics has impacted the daily clinical treatment of patients with MBC. In this study, we determine whether including MBC patients in clinical trials affects clinical outcomes.MethodsWe retrospectively reviewed data for a total of 863 patients diagnosed with initial or recurrent (after receiving adjuvant systemic treatments following surgery) metastatic disease between January 2000 and December 2013. Data were obtained from the breast cancer database of Samsung Medical Center.ResultsAmong the 806 patients selected for inclusion, 188 (23%) had participated in clinical trials. A total of 185 clinical trials were conducted from 2000 to 2014. When compared with earlier periods (n = 10 for 2000–2004), clinical trial enrollment significantly increased over time (n = 103 for 2005–2009, P = 0.024; n = 110 for 2010–2014, P = 0.046). Multivariate analyses revealed that biologic subtype, distant recurrence free interval (DRFI), and clinical trial enrollment were independent predictors of overall survival. Patients who participated in clinical trials showed improved survival, with a hazard ratio of 0.75 (95% CI, 0.59–0.95), which was associated with a 25% reduction in the risk of death. However, subgroup analysis showed that this improved survival benefit was not maintained in patients with triple negative breast cancer (TNBC).ConclusionsAlthough not conclusive, we could speculate that there were differences in the use of newer agents or regimens over time, and these differences appear to be associated with improved survival.

Demographic and clinicopathologic characteristics of 22,812 cases of triple negative first primary female breast cancer from the California Cancer Registry 2000–2014.

The number of deaths in Denmark decreased steadily from 2000 to 2014, when it was just above 50,000. However, it has increased since, standing at 58,000 in 2023. The number of deaths was higher among women than men until 2014, when the death numbers of men started to be higher. In 2022, 30,000 men and around 29,000 women died.

The most common cause of death

The most common cause of death in 2021 was cancerous tumors (malignant neoplasms), which caused around 16,000 deaths. Lung cancer caused the highest number of deaths After cancerous tumors, heart diseases was the most common cause of death.

 Cancer

In 2020, over 45,000 new cases of cancer were diagnosed among patients in Denmark. For men, the most commonly found type of cancer was genital cancer, with almost 5,000 new cases. For women, the most common type of cancer was breast cancer, with over 5,000 new cases.

Cancer diagnoses and age-standardised incidence rates for all types of cancer by age and sex including breast, prostate, lung and colorectal cancer.

In the United States, the leading causes of death among women are heart disease and cancer. Heart disease and cancer are similarly the leading causes of death among U.S. men. In 2023, heart disease accounted for **** percent of all deaths among women in the United States, while cancer accounted for **** percent of deaths. COVID-19 was the third leading cause of death among women in 2020 and 2021, and the fourth leading cause in 2022, however, by 2023 it had dropped to ninth place. Cancer among women in the U.S. The most common types of cancer among U.S. women are breast, lung and bronchus, and colon and rectum. In 2025, there were around ******* new breast cancer cases among women, compared to ******* new cases of lung and bronchus cancer. Although breast cancer is the most common form of cancer among women in the United States, lung and bronchus cancer causes the highest number of cancer deaths. In 2025, around ****** women were expected to die from lung and bronchus cancer, compared to ****** from breast cancer. Breast cancer Although breast cancer is the second most deadly form of cancer among women, rates of death have decreased over the past few decades. This decrease is possibly due to early detection, progress in therapy, and increasing awareness of risk factors. In 2023, the death rate due to breast cancer was **** per 100,000 population, compared to a rate of **** per 100,000 in the year 1990. The state with the highest rate of deaths due to breast cancer is Oklahoma, while South Dakota had the lowest rates.

Data by medical encounter for the following conditions by age, race/ethnicity, and gender:

Acute Myocardial Infarction (AMI)
Asthma
Bladder Cancer
Brain Cancer
Coronary Heart Disease (CHD)
Colorectal Cancer
Chronic Obstructive Pulmonary Disease (COPD)/Chronic Lower Respiratory Diseases
Diabetes
Female Breast Cancer
Female Reproductive Cancer
Heart Failure
Hyperlipidemia (High Blood Cholesterol)
Kidney Cancer
Leukemia
Liver Cancer Lung Cancer Lupus and Connective Tissue Disorders
Melanoma of the Skin
Non-Hodgkin's Lymphoma
Non-melanoma Skin Cancer
Overall Cancer
Overall Heart Disease
Overall Hypertensive Diseases
Pancreatic Cancer
Prostate Cancer Stroke
Thyroid Cancer

Rates per 100,000 population. Age-adjusted rates per 100,000 2000 US standard population.
Blank Cells: Rates not calculated for fewer than 11 events. Rates not calculated in cases where zip code is unknown. Geography not reported where there are no cases reported in a given year. SES: Is the median household income by SRA community. Data for SRAs only.
*The COVID-19 pandemic was associated with increases in all-cause mortality. COVID-19 deaths have affected the patterns of mortality including those of Non-Communicable conditions.

Data sources: California Department of Public Health, Center for Health Statistics, Office of Health Information and Research, Vital Records Business Intelligence System (VRBIS). California Department of Health Care Access and Information (HCAI), Emergency Department Database and Patient Discharge Database, 2020. SANDAG Population Estimates, 2020 (vintage: 09/2022). Population estimates were derived using the 2010 Census and data should be considered preliminary. Prepared by: County of San Diego, Health and Human Services Agency, Public Health Services, Community Health Statistics Unit, February 2023.

This table contains 238 series, with data for years 2000 - 2004 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (14 items: Canada; Nova Scotia; Prince Edward Island; Newfoundland and Labrador ...), Sex (3 items: Both sexes; Males; Females ...), Selected causes of death (ICD-10) (7 items: Colorectal cancer; Lung cancer; Female breast cancer; Prostate cancer ...).

Guarapari, a municipality of the state of Espírito Santo, Brazil, reported higher mortality rates for the most common cancers from 1996 to 2000. This municipality has beaches with high natural radioactivity. To verify whether this excessive cancer mortality rate still exist in Guarapari, mortality rates for all causes, cancers, and the most prevalent cancers in this municipality were studied from 2000 to 2018 and compared with those observed in the state. Data on all-cause mortality, all-cancer mortality, and mortality from cancer of the esophagus, stomach, larynx, trachea, bronchi and lung, prostate, breast, and leukemias were collected in Brazilian Health Informatics Department (DATASUS) from 2000 to 2018. Mortality rates were calculated by direct method. Standardized age-adjusted rates (SAAR) were calculated based on standard of the World Health Organization (WHO) world population. Crude mortality rates were calculated for each municipality and SAAR for the state and nine municipalities where natural radioactivity was evaluated. Mortality rates from all causes, all cancers, and different cancers observed in Guarapari did not differ significantly from those observed in the state or municipalities with more than 100,000 inhabitants. Radioactivity levels and mortality rates showed no correlation in nine municipalities where natural radioactivity was known. In conclusion, results showed that mortality from cancer and all causes in Guarapari did not differ from those observed in the state and that there was no correlation between the levels of natural radioactivity and mortality from cancer in areas where natural radioactivity was evaluated.